> Details

Yildirim, Mahmut Emre; Karadurmuş, Nuri; Ökten, İlker Nihat; Türk, Hacı Mehmet; Urakçı, Zuhat; Arslan, Çağatay; Çelik, Sinemis; Dane, Faysal; Şendur, Mehmet Ali Nahit; Bilir, Cemil; Karabulut, Bülent; Cicin, İrfan; Çubukçu, Erdem; Karaca, Mustafa; Ozcelik, Melike; Artaç, Mehmet; Tanrikulu, Eda; Alacacioglu, Ahmet; Açıkgöz, Özgür; Öven, Başak; Geredeli, Çağlayan; Çil, Timucin; Harputluoğlu, Hakan; Kefeli, Umut; [...]

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
  • Contributor: Yildirim, Mahmut Emre; Karadurmuş, Nuri; Ökten, İlker Nihat; Türk, Hacı Mehmet; Urakçı, Zuhat; Arslan, Çağatay; Çelik, Sinemis; Dane, Faysal; Şendur, Mehmet Ali Nahit; Bilir, Cemil; Karabulut, Bülent; Cicin, İrfan; Çubukçu, Erdem; Karaca, Mustafa; Ozcelik, Melike; Artaç, Mehmet; Tanrikulu, Eda; Alacacioglu, Ahmet; Açıkgöz, Özgür; Öven, Başak; Geredeli, Çağlayan; Çil, Timucin; Harputluoğlu, Hakan; Kefeli, Umut; [...]
  • imprint: SAGE Publications, 2024
  • Published in: Journal of Oncology Pharmacy Practice
  • Language: English
  • DOI: 10.1177/10781552241241004
  • ISSN: 1078-1552; 1477-092X
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Backgrounds and Objectives</jats:title><jats:p> Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311). </jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p> In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively ( p  =  0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively ( p  =  0.848). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments. </jats:p></jats:sec>